Terence Friedlander, MD

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

Terence W. Friedlander, MD, discusses updates in the frontline management of bladder cancer.

Terence W. Friedlander, MD, discusses the investigation of BT8009 in the Duravelo-2 study in patients with advanced or metastatic urothelial cancer.

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.